Published in Int J Cancer on May 20, 2017
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 7.16
CpG island methylator phenotype in cancer. Nat Rev Cancer (2004) 7.13
Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res (1993) 4.93
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology (2002) 3.70
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res (2008) 2.83
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut (2008) 2.68
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res (2010) 2.23
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer (2010) 2.16
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst (2007) 2.11
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00
Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol (2003) 1.90
Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84
CIMP, at last. Gastroenterology (2005) 1.74
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 1.67
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch (2007) 1.57
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int (2008) 1.52
The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta (2011) 1.43
Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol (2012) 1.37
Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol (2003) 1.36
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol (2015) 1.30
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One (2010) 1.26
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol (2014) 1.21
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology (2014) 1.13
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res (2012) 1.11
Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) (2015) 1.05
Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch Pathol Lab Med (2008) 1.01
Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer (2010) 1.01
Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics (2012) 0.98
Important molecular genetic markers of colorectal cancer. Oncotarget (2016) 0.94
Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics (2016) 0.84
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer (2016) 0.83
Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. Clin Cancer Res (2015) 0.81
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer (2016) 0.79
Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Methylation status in patients with early stage colon cancer: a new prognostic marker? Int J Cancer (2011) 0.77